Summarized by Masters of Longevity from FDA - Drugs.
FDA approved asundexian with antiplatelet therapy to reduce recurrent stroke risk.
Key Takeaways
- Asundexian is approved to reduce recurrent non-cardioembolic stroke risk.
- Approval is for adults after recent mild-to-moderate ischemic stroke.
- Approval is for use together with antiplatelet therapy to reduce risk.
